WARNING: $NVO temporarily down 10%. Ziltivekimab failed in Phase 3, as the drug did not demonstrate the expected risk reduction for serious cardiovascular events. I’ve been saying for years: NVO is not currently investable, as it simply lacks the right products compared to its competitors. This is another reminder that a low price does not automatically mean "cheap" or a good value. How many warning signs are still needed... or am I missing something?
Dr. Julian HospShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.